Solace Lifesciences, Inc. — Form D/A

Solace Lifesciences, Inc. of WILMINGTON, DE, a company, filed a Form D amendment with the SEC on 2017-12-14. The offering totals $4.0M, of which $1.6M was reported sold. Industry: Other Health Care.

Offering

Filed: 2017-12-14
Form: D/A
Accession: 0001502380-17-000001
Industry: Other Health Care
Exemptions: 06b
Total offering: $4.0M
Amount sold: $1.6M
Remaining: $2.4M
Minimum investment: $25K
Investors: 43
Date of first sale: 2015-06-02
Security types: equity
Revenue range: $1 - $1,000,000
SEC file number: 021-239012

Issuer

Name: Solace Lifesciences, Inc.
CIK: 0001502380
Entity type: Corporation
Jurisdiction: DELAWARE
Incorporated: 2010
Address: 501 SILVERSIDE ROAD #7, WILMINGTON, DE, 19809
Phone: 877-668-2256

Officers, directors & promoters (13)

Name	Role	Location
Christopher C Gross	Director	Wilmington, DE
Garrett C Holloway	Director	Wilmington, DE
Stephen C Kujawa	Director	Wilmington, DE
David C Pilzner	Director	Wilmington, DE
Christopher C Gross	Executive Officer	Wilmington, DE
James M Poole	Director	Wilmington, DE
James M Poole	Executive Officer	Wilmington, DE
Stephen G Kujawa	Director	Wilmington, DE
David G Pilzner	Director	Wilmington, DE
Christopher G Gross	Director	Wilmington, DE
Christopher G Gross	Executive Officer	Wilmington, DE
Garrett G Holloway	Director	Wilmington, DE
David C Allen	Director	Kerrville, TX

Other filings by this issuer (3)

Filed	Form	Offering	Sold
2018-12-07	D	$5.0M	—
2015-05-01	D	$4.0M	—
2010-10-06	D	$2.0M	$50K

More